NCT05989152 Evolution of PET Fixation With FDG at the End of Antibiotic Treatment of Infective Endocarditis on Valvular Prosthesis
| NCT ID | NCT05989152 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Prosthetic Valve Endocarditis |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-04-17 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-04-17 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients with prosthetic valve endocarditis (PVE) and pathological valvular FDG uptake on the initial FDG-PET and not referred to valve replacement at the acute phase, the study will assess whether FDG-PET is able to identify those at increased risk of PVE relapse.
Eligibility Criteria
"Inclusion criteria: * Patient aged 18 or over; * Have a prosthetic valve implanted surgically or by catheter for at least 3 months; * Presenting a definite IE on a prosthetic valve (ESC definition in force); * Having benefited from an FDG-PET examination for diagnostic purposes as part of the treatment revealing pathological hyperuptake at the level of the prosthetic valve AND carried out \<15 days after the start of antibiotic therapy for infective endocarditis; * Absence of cardiac surgical intervention performed for the current episode of AE or planned before the end-of-treatment FDG-PET Exclusion criteria: * Patient under legal protection, guardianship or curators; * Pregnancy, breastfeeding; * Patient not affiliated to a health insurance scheme or not a beneficiary of a social security scheme; * Simultaneous participation in a study on FDG-PET; * Absence of informed consent signed by the patient."
Contact & Investigator
François Rouzet, MD, PHD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05989152 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prosthetic Valve Endocarditis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05989152 currently recruiting?
Yes, NCT05989152 is actively recruiting participants. Contact the research team at francois.rouzet@aphp.fr for enrollment information.
Where is the NCT05989152 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05989152 clinical trial?
NCT05989152 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is François Rouzet, MD, PHD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 50 participants.